--- title: "Survodutide Peptide SA - Compare Prices from 0 Suppliers - PeptideSupermarket®" description: "Compare Survodutide prices from 0 SA suppliers. Find the cheapest deals, read reviews and save money." url: "https://peptidesupermarket.co.za/peptide/survodutide" site: "PeptideSupermarket®" country: "South Africa" --- [Home](https://peptidesupermarket.co.za) › [Peptides](https://peptidesupermarket.co.za/compare-peptide-prices-za) › Survodutide Search # Survodutide Price Comparison Live prices from 0 SA suppliers, compared side by side so you never overpay. [GLP-1 & metabolic research](https://peptidesupermarket.co.za/compare-peptide-prices-za) We compare prices & may earn a commission. [Full disclosure](https://peptidesupermarket.co.za/disclosure). 0 results ### No products found We haven't found any suppliers listing this peptide yet. Check back soon as we update our database regularly. More ways to compare Survodutide Different views of the same live SA pricing, tuned for how you like to shop. [Best Survodutide Prices Best prices ranked](https://peptidesupermarket.co.za/best-survodutide-prices) [Cheapest Survodutide Prices Cheapest suppliers compared](https://peptidesupermarket.co.za/cheapest-survodutide-prices) [Where to Buy Survodutide Full buyer's guide](https://peptidesupermarket.co.za/where-to-buy-survodutide) [Buy Survodutide Online SA Cheap Today's hottest deals](https://peptidesupermarket.co.za/buy-survodutide-online-za-cheap) [Survodutide Price Comparison Live price dashboard](https://peptidesupermarket.co.za/survodutide-price-comparison) [Survodutide SA Supplier Verified SA supplier directory](https://peptidesupermarket.co.za/survodutide-za-supplier) [Survodutide For Sale Browse listings for sale](https://peptidesupermarket.co.za/survodutide-for-sale) Compare another peptide Search PeptideSupermarket® compares prices but doesn't sell products. More All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed. We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed. By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. [Read our full disclosure](https://peptidesupermarket.co.za/disclosure). ## Survodutide Profile Extensively Studied Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes ### Overview Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy. ### Mechanism of Action Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R. ### Key Benefits - Superior weight loss vs monotherapy (14.9% at 46 weeks) - Once-weekly convenient dosing - Proven efficacy in obesity, MASH, and Type 2 diabetes - 62% MASH improvement in clinical trials ### Quick Stats Typical Dose 0.6mg starting, titrate up to 3.6-6.0mg weekly Frequency Once weekly (same day each week) Cycle Duration 24-76+ weeks continuous therapy Storage Reconstituted: 2-8°C immediately after mixing ## Molecular Information Molecular Weight ~4,500 Da Length 29 amino acids Type Peptide with fatty acid acylation Half-Life Approximately 6 days (109-115 hours) ### Amino Acid Sequence `29-amino acid peptide` ### Modifications C18 fatty acid acylation for extended half-life (~6 days) ## Research Indications The following information is derived from published scientific literature and is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. These peptides are not approved for human use and are sold exclusively for in-vitro laboratory research. Weight Loss Metabolic ## Dosing Protocols ### injectable Subcutaneous injection to abdomen (2+ inches from navel), upper thigh, or upper arm. Any time of day, with or without food. | Goal | Dose | Frequency | Route | | --- | --- | --- | --- | | Obesity - Conservative Start | 0.6mg titrated over 24 weeks | Once weekly with 4-week intervals | SubQ | | Obesity - Standard Protocol | 3.6-6.0mg | Once weekly | SubQ | | MASH Treatment | 2.4-4.8mg | Once weekly | SubQ | | Type 2 Diabetes | 0.3-2.7mg | Once weekly | SubQ | #### Key Tips - Once-weekly dosing convenience - ~6 day half-life - Balanced dual agonism Reconstitution Instructions ## Peptide Interactions #### Semaglutide/Tirzepatide Monitor Both GLP-1 agonists; combining risks excessive activation and GI side effects. #### Metformin Compatible Demonstrated together in Phase 2 diabetes trials. #### SGLT2 Inhibitors Compatible No known interactions; allowed in Phase 3 with monitoring. #### Sulfonylureas Monitor Hypoglycemia risk; consider dose reduction. #### Insulin Monitor May require insulin dose reduction due to improved glycemic control. #### Oral Contraceptives Monitor Take 1+ hour before survodutide due to delayed gastric emptying. #### Other Glucagon Agonists Avoid Risk of excessive glucagon receptor activation. ## What to Expect Weeks 1-4 Possible nausea, reduced appetite (most common during escalation) Weeks 4-8 Initial weight loss begins; improved satiety between meals Weeks 8-16 Progressive weight loss; potential energy level improvements Weeks 16-24 Approaching steady-state; more consistent effects Weeks 24+ Sustained weight loss; average 15-19% by week 46 ## Side Effects & Safety #### Common Side Effects - Nausea (40-66%) - Diarrhea (25-49%) - Vomiting (15-41%) - Slight heart rate increase (mean 2-5 bpm) #### Monitoring - Monitor blood glucose if on diabetes medications - No dose adjustment needed for hepatic impairment (including cirrhosis) - Monitor heart rate in patients with cardiac conditions #### Stop Signs - Severe persistent nausea/vomiting preventing oral intake - Signs of pancreatitis (severe abdominal pain radiating to back) - Allergic reactions (rash, itching, difficulty breathing) - Severe hypoglycemia with insulin/sulfonylureas - Gallbladder symptoms (right upper quadrant pain) - Significant tachycardia or arrhythmias #### Contraindications - Not recommended in pregnancy or breastfeeding - Use contraception during treatment ## Quality Checklist #### Good Signs - Clear to slightly opalescent solution without visible particles - Sealed vial with intact rubber stopper - Within expiration date #### Warning Signs - Slight foam after reconstitution is normal if disappears within minutes #### Bad Signs - Cloudy solution or visible particles indicates contamination - Discoloration of powder or solution ## Research & References ### Key References 1. 2024 #### Phase 2 Obesity Trial Without Diabetes 387 participants; BMI ≥27 kg/m²; 46 weeks. 14.9% mean weight loss at 4.8mg; 83% achieved ≥5%, 69% achieved ≥10%, 55% achieved ≥15%. 2. 2024 #### Phase 2 MASH and Fibrosis Trial 293 participants with biopsy-confirmed MASH; 48 weeks. MASH improvement: 62% (4.8mg) vs 14% placebo; 63-67% achieved ≥30% liver fat reduction. 3. 2023 #### Phase 2 Type 2 Diabetes Trial Head-to-head vs semaglutide 1.0mg; 16 weeks. Survodutide -8.7% weight loss vs semaglutide -5.3%; HbA1c reduction up to -1.6%. [Search PubMed for Survodutide](https://pubmed.ncbi.nlm.nih.gov/?term=%28%22Survodutide%22%20OR%20%22BI%20456906%22%29) --- *Add `.md` to any page URL on peptidesupermarket.co.za for its Markdown version. Index of the site: https://peptidesupermarket.co.za/llms.txt - full text: https://peptidesupermarket.co.za/llms-full.txt.*